SCHEMBL765231

SCHEMBL765231

O=NCCN=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14612540 0.78
SCHEMBL463669 0.78
SCHEMBL6050015 0.78
SCHEMBL14048657 0.75
SCHEMBL7269245 0.75
SCHEMBL6050020 0.75
SCHEMBL14388446 0.73
SCHEMBL8902145 0.71
SCHEMBL14747658 0.71
SCHEMBL3033319 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105070528-B A kind of ultracapacitor electrolyte 湖南中大新能源科技有限公司 2017-12-22 CN disclosed
EP-2781961-B1 TONER FOR ELECTROSTATIC IMAGE DEVELOPMENT, PRODUCTION METHOD OF THE TONER AND IMAGE FORMATION METHOD KONICA MINOLTA INC (JP) 2017-12-20 EP disclosed
EP-2861670-B1 METAL FREE REACTIVE DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE DYSTAR COLOURS DISTRIB GMBH (DE) 2017-08-16 EP disclosed
EP-2812332-B1 METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE PRODRUG COMPOUND VIIV HEALTHCARE UK (NO 4) LTD (GB) 2017-08-09 EP disclosed
US-20170106065-A1 Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3 BAVARIAN NORDIC A/S (DK) 2017-04-20 US disclosed
EP-3087988-A2 USE OF INHIBITORS OF TOLL-LIKE RECEPTORS IN THE PREVENTION AND TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA AND DISEASES RELATED THERETO Idera Pharmaceuticals, Inc. (US) 2016-11-02 EP disclosed
US-9452961-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2016-09-27 US disclosed
EP-2982679-A1 IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE Idera Pharmaceuticals, Inc. (US) 2016-02-10 EP disclosed
EP-2960333-A1 COMPOSITION FOR INHIBITING GENE EXPRESSION AND USES THEREOF Idera Pharmaceuticals, Inc. (US) 2015-12-30 EP disclosed
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US disclosed
US-20130065853-A1 CONTRACEPTIVE METHODS AND COMPOSITIONS THE WASHINGTON UNIVERSITY (US) 2013-03-14 US disclosed
US-8137669-B2 Elimination of heterogeneous or mixed cell population in tumors IMMUNOGEN, INC. (US) 2012-03-20 US disclosed
EP-2069354-B1 Aza-benzofuranyl compounds and methods of use GENENTECH INC (US) 2011-11-02 EP disclosed
EP-1709193-B1 METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES UNIV CALIFORNIA (US) 2011-03-16 EP disclosed
US-7517658-B2 Methods for preparing compositions using a SNORF33 receptor H. LUNDBECK A/S (DK) 2009-04-14 US disclosed
US-7410773-B2 Method of preparing an undifferentiated cell GHAZI JASWINDER DHOOT (DE) 2008-08-12 US disclosed
EP-1343389-B1 MELTABLE FORM OF SUCRALOSE TATE & LYLE TECHNOLOGY LTD (GB) 2008-05-07 EP disclosed
EP-1019494-B1 STIMULATION OF HEMATOPOIETIC CELLS IN VITRO POINT THERAPEUTICS INC (US) 2007-03-21 EP disclosed
US-20070028315-A1 DNA encoding SNORF33 receptor H. LUNDBECK A/S (DK) 2007-02-01 US disclosed
EP-1184454-B1 Nav2 channel gene-deficient non-human animals JP OKAZAKI NAT RES INST (JP) 2007-01-24 EP disclosed